AstraZeneca's Enhertu Cancer Treatment Reduced Risk of Disease Progression by 72%
By The CCM Team
AstraZeneca PLC said Monday that its cancer treatment Enhertu reduced the risk of disease progression or death by 72% in patients with HER2-positive metastatic breast cancer.
HER2 refers to a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2.
Have a medical story to share? Schedule a Consultation
The U.K. pharmaceutical giant said that the DESTINY-Breast03 Phase 3 trial showed that Enhertu demonstrated superior progression-free survival versus trastuzumab emtansine, a HER2-directed antibody drug conjugate currently approved to treat patients with HER2-positive unresectable--unable to be removed by surgery--and/or metastatic breast cancer previously treated with trastuzumab and a taxane--a type of drug that blocks cell growth.
Read more on the Enhertu webiste
